InnoSer

🔬Live videos from our neurology labs shows some of the exciting experiments that our research teams are conducting on a daily basis.  In this experiment, InnoSer scientists have compared the neuromuscular function of healthy (WT) and diseased research subjects (C3-PMP22 research model of Charcot Marie Tooth Disease Type 1A, #CMT1A). Briefly, the hindlimbs of the research models have been stimulated and compound muscle action potentials (#CMAPs) recorded, showing significant changes in CMAP compared to healthy subjects. Calculation of latency and CMAP annotation are performed manually by our scientists to ensure accurate results. All in all, this confirms that this research model of CMT1A has significantly impaired neuromuscular function, confirming its suitability as a preclinical research model for efficacy testing of novel CMT1A targeted treatments.  👉 Read more about the C3-PMP22 model of #CMT1A here: https://lnkd.in/eSEm96Z4 👉 Interested in using the C3-PMP22 mouse model for your research? Don’t hesitate to contact us for more information here: https://lnkd.in/eHH4bmZT #SeeCMT #NavigatingCMT #NeuroscienceResearch #NeurologyCRO #NeuroscienceCRO #EuropeanNeurologyCRO #CharcotMarieToothDisease 

Today on #ResearchAppreciationDay, we celebrate the incredible contributions of researchers around the world. Their tireless efforts drive innovation, enhance our understanding of complex issues, and pave the way to better health. Drawing attention specifically to our research team. We want to thank our preclinical researchers and their diligence in testing the feasibility, safety, and potential efficacy of new treatments before they can progress through to clinical trials. 👏🏻 Let’s take a moment to appreciate and support the brilliant minds who dedicate their lives to pushing the boundaries of human knowledge. Tag a researcher you're proud of below!

📰 📢 Tune in to July’s InnoSer newsletter highlighting the latest research news from our laboratories! Click and open the newsletter to read all of the exciting updates from InnoSer. A summary of updates is shown below👇.  🔬This month’s highlights from our #Neuroscience labs focus on characterization data of a human transgenic #TDP43 mouse model of #ALS. The new characterization data includes #CMAP and #NfL plasma protein quantification, confirming the neurodegenerative disease phenotype in the TDP-43 ALS research model. 🔬We have also recently welcomed a new portfolio update, and InnoSer now offers specialized preclinical research services in a #SpinalCordInjury research model.  🔬 Our #oncology update showcases the importance of spatial immunofluorescent analyses in the context of #Immunotherapy drug development.  🔬 Our #ADPKD #Nephrology update highlights further validation data our scientists have obtained using the #AMPKActivator #Salsalate to serve as a positive control in the #ADPKDMouseModel, helping you maximise the translational value of your preclinical research.  🔬 InnoSer’s team is also happy to announce that we are now offering comprehensive in vitro services to evaluate and detect potential #nephrotoxicity of novel investigational compounds to help de-risk drug development using conditionally immortalized proximal tubule epithelial cells #ciPTEC.   #PreclinicalResearch #DrugDevelopment #ImmunoOncology #Nephrology #RareDiseases #Immunology #CRO #Neurology #Neuroscience #EuropeanCRO #ImmunoOncologyCRO #NeuroscienceCRO #ADPKDCRO #RareDiseaseCRO 

JULY IS FRAGILE X SYNDROME AWARENESS (#FXS) MONTH! Raising awareness about Fragile X Syndrome is crucial for early diagnosis, intervention, and support. As a rare disease, Fragile X often faces challenges in research funding, leading to delays in developing effective treatments and therapies. By increasing awareness, we can drive more research and funding to better understand and manage this condition. As part of InnoSer's rare disease portfolio, we offer specialized preclinical research services using a relevant research model, allowing for efficacy testing of targeted interventions. For more information on this model and the readouts we use to assess efficacy of putative FXS treatment strategies, please refer to our website: https://lnkd.in/eqEJb7qr #FragileXSyndromeAwareness #FXSAwareness #PreclinicalNeuroscienceCRO #RareDiseaseAwareness #RareDiseaseCRO #EuropeanNeuroscienceCRO #DrugDevelopment

Catch our business development manager, Charlotte Wuyts at today's #DutchBiotechEvent2024 organized by hollandbio to discuss how InnoSer can help your #Biotech accelerate your preclinical research. Are you not attending the event but still interested in learning more about how you can benefit from InnoSer's extensive preclinical expertise? Reach out to us here: https://lnkd.in/eHH4bmZT. #ContractResearch #EuropeanCRO #ImmunoOncologyCRO #NeuroscienceCRO #PreclinicalCRO #DrugDevelopmentCRO

For today's #FluorescenceFriday we are sharing this beautiful multiplex immunofluorescence (IF) staining of a tumor microenvironment (TME). Images show an example of multiplex IF analyses on tumor samples obtained from MC38 colorectal adenocarcinoma samples (subcutaneously implanted) from untreated (vehicle) and anti-PD-1 treated mice. 🔬 This tumor sample staining obtained from MC38 adenocarcinoma mouse model (implanted subcutaneously) showcases a multiplex panel of antibodies to detect B-cells (beige), colorectal cancer cells (red), epithelium (purple), M1 macrophages (light blue), M2 macrophages (dark blue), neutrophils (green), T-cells (yellow), cytotoxic T-cells (light orange) and T-helper cells (gray). 🔬Highlighted areas show preserved spatial analyses showcasing tumoral area (red), peritumoral (yellow) and non-tumoral area (green). Besides defining areas in the tissue, spatial TME analyses are useful to study cellular phenotypes in the tissue context as well as studying cell-cell interactions using complex bioinformatic analyses (i.e., neighbourhood and nearest neighbour analysis).  👉 Continue reading the full case study on our webpage: https://lnkd.in/ePFZnSYW 👉 View InnoSer's solutions for immuno-oncology research here: https://lnkd.in/dtBrJD5E 👉 Discover the value of including TME profiling as a readout for your preclinical research now: https://lnkd.in/eHH4bmZT #EuropeanOncologyCRO #ImmunoOncologyCRO #OncologyCRO #ContractResearchServices #DrugDevelopment #PKPDProfiling #Bioanalysis #ContractResearch

A new publication using InnoSer’s ADPKD mouse model shows that computational drug discovery approaches arise as an attractive way to identify and understand potential new treatments for traditionally underserved rare diseases. In this paper, researchers from Healx show that the anti-parasitic drug, Mebendazole, is a potent anti-cystic agent, ameliorating the diseased kidney phenotype of ADPKD mice. This was marked by a decrease in cystic index, reduction in kidney volume, and blood urea levels in ADPKD mice. This research shines light on novel drug discovery approaches, aimed to support the discovery and development of novel therapeutics to treat #RareDiseases such as #ADPKD.  Continue reading the paper here: https://lnkd.in/eKTtFrse  Read more to discover how you can leverage InnoSer’s #ADPKD model and expertise in nephrology in your drug development journey here: https://lnkd.in/gM74_eg  #AutosomalDominantPolycysticKidneyDisease 

📰 📢 Tune in to June’s InnoSer newsletter highlighting the latest research news from our laboratories! This month’s highlights from our #Neuroscience labs focus on characterization data of a spinal cord injury #SCI research model.  

New publication co-authored by the InnoSer team (former Sylics) shows that #AutomatedBehaviorMonitoringSystem can be used to reproducibly dissect sex differences in spontaneous behavior and cognition in mice. Differences between male and female mice in spontaneous behaviors such as activity may be an important consideration when designing behavioral studies. Read more about the methodology and results here: https://lnkd.in/d84t_U8M At InnoSer, we frequently work with multiple conventional and automated home-cage behavioral assays. Behavioural testing provides crucial insights into the underlying disease mechanisms, as well as readouts that can be used for preclinical efficacy studies. This allows drug developers to determine the efficacy, safety as well as potential adverse effects of such compounds before progressing to clinical trials.  Automated home-cages collect a wealth of longitudinal behavioural phenotyping data in a highly standardized manner, without the need for human intervention. Automated home-cages have additional advantages, relating to both efficiency of the experiment, but also the influence on rodent’s behaviour. Read more about InnoSer’s expertise and experience in behavioral testing for precliincial research here: https://lnkd.in/e6xbW23y #EuropeanNeuroscienceCRO #NeurologyCRO #NeuroscienceCRO #PreclinicalCRO #DrugDevelopment #NeurodegenerativeDiseaseCRO #RareDiseaseCRO #BehavioralTestingCRO

🔬Our oncology webpages have recently gone through a revamp! Now you can easily navigate through InnoSer's oncology portfolio offering spanning from immuno-oncology in vitro assays to patient-derived xenograft (PDX) mouse models. 👉 View each model webpage, browse through example data and possible readout types now: https://lnkd.in/dtBrJD5E #OncologyCROServices #EuropeanOncologyCRO #ImmunoOncology #SyngeneicMouseModels #CellLineDerivedMouseModels #PatientDerivedOrganoids #HumanizedMouseModels